✓ Dopamine agonists (DA) are first line therapy for Prolactinoma which normalises prolactin (PRL) level in 80% of cases at a median weekly dose of 1mg.
✓ An accepted criterion of pharmacological resistance to DA is failure to normalize PRL levels.
✓ Failure to normalize PRL levels is seen in 24% of those treated with bromocriptine, 13% of those treated with pergolide and 11% of those treated with cabergoline.
✓ Although most patients who respond to dopamine agonists with a normalization of PRL levels have substantial tumour size reduction not all do and viceversa.
✓ We report a case of aggressive macroprolactinoma that required 7mg of Cabergoline to reduce prolactin despite radiological evidence of tumour shrinkage.
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❖ Summary:
▪ Resistance to dopamine agonists can be defined with respect to failure to normalize PRL levels and failure to decrease tumor size by ≥50% ▪ This case highlights marked secondary resistance to Cabergoline following an initial favourable response.
▪ Secondary resistance to DA occurs rarely but this case demonstrates that effective tumour shrinkage can be obtained with higher doses of cabergoline with careful monitoring of adverse effects.
▪ Once tumour shrinkage has been achieved the dose of cabergoline should be reduced to the lowest effective dose that maintains a stable prolactin level.
▪ Complete normalisation of prolactin may not be feasible or indicated in the majority of cases.
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❖ Case Summary:
o A 42 year old male presented with a bitemporal field defect and his imaging confirmed an invasive macroprolactinoma. o His biochemical profile showed elevated PRL level of 91,760 mU/L and hypogonadotropic hypogonadism (FSH-3.3 u/L, LH-2.5 u/L; testosterone-6.2 nmol/L). o The patient was started on 500 mcg of Cabergoline per week and the dose was titrated to 1 mg/week. o After 6 months there was marked reduction in the size of the tumour which was accompanied by a fall in prolactin to 10,6050 mU/L . o Thereafter, prolactin level remained static and the dose of Cabergoline was progressively titrated to a maximum of 7mg weekly. o Repeat MRI scan showed complete shrinkage of macroprolactinoma however, the prolactin remained persistently elevated at 1,826mU/l. o This dose was associated with adverse effects and the dose of cabergoline was reduced gradually to a maintenance dose of 500 mcg weekly. o Prolactin remains slightly elevated at 2037mU/l but is stable with no associated increase in tumour size. 
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